| |
Fluoxetine (n=42) |
Placebo (n= 42) |
| Mean Age (years) |
59.93±8.400 |
57.62±8.115 |
| Male |
29(69%) |
25(59.5%) |
| Vascular risk factors |
|
|
| Diabetes |
7(16.7%) |
6(14.3%) |
| Hypertension |
39(92.9%) |
42(100%) |
| Dyslipidaemia |
7(16.7%) |
6(14.3%) |
| Current smoker |
17(40.5%) |
13(31%) |
| Haemorrhage characteristics |
|
|
| location |
|
|
| putamen |
22(52.4%) |
23(54.8%) |
| thalamus |
20(47.6%) |
19(45.2%) |
| Average volume (ml) |
35.12 ± 12.272 |
36.21 ± 12.869 |
| Baseline stroke severity |
|
|
| Total FMMS score |
18.31 ± 2.509 |
19.40 ± 2.548 |
| Upper limb FMMS score |
7.45 ± 1.173 |
8.19 ± 1.311 |
| Lower limb FMMS score |
10.86 ± 1.671 |
11.21 ± 1.415 |
| NIHSS score |
13.60 ±2.275 |
13.48 ±2.200 |
| Modified Rankin scale score |
|
|
| 0-2 |
0(0.00%) |
0(0.00%) |
| 3 |
2(4.76%) |
2(4.76%) |
| 4 |
17(40.48%) |
20(47.6%) |
| 5 |
23(54.76%) |
20(47.6%) |
| MADRS score |
4.38±3.060 |
4.55 ±2.568 |
| Time from stroke to treatment (days) |
9·1 (1·6) |
9.3 (1·6) |
|
